Pharmaceutical maker GlaxoSmithKline will pay 44 states, including Connecticut, a total $105 million settlement to resolve allegations that it unlawfully promoted three of its drugs, Attorney General George Jepsen’s office announced Wednesday.
Connecticut’s share of the settlement is $1.6 million, most of which will go to the general fund, Jepsen said.
GSK was accused of violating state consumer protection laws by making promotional claims not approved by the U.S. Food and Drug Administration about the uses and qualities of asthma drug Advair and antidepressants Paxil and Wellbutrin.
In agreeing to pay the settlement, the company did admit any wrongdoing or violation of any laws.
As part of the settlement, GSK will be required to reform its marketing practices, not promote any drugs for off-label uses, and continue a program meant to reduce incentives for drug sales representatives to engage in deceptive marketing.
